Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
DESCRIPTION: The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2013 on lipid management and treatment of all adults and children with chronic kidney disease (CKD). All forms of CKD are included (non-dialysis-dependent, dialysis-dependent, and kidney transplant recipients). METHODS: The KDIGO Lipid Guideline Development Work Group defined the scope of the guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence that had been summarized by an evidence review team. Searches of the English-language literature were conducted through August 2011 and supplemented by targeted searches through June 2013. Final modification of the guidelines was informed by the KDIGO Board of Directors and a public review process involving registered stakeholders. RECOMMENDATIONS: The full guideline includes 13 recommendations; a key element was the recommendation for statin or statin with ezetimibe treatment of adults aged 50 years or older with estimated glomerular filtration rates less than 60 mL/min/1.73 m2 but not treated with long-term dialysis or kidney transplantation. This synopsis focuses on 8 recommendations pertinent to assessment of lipid status and treatment with a statin-based regimen in adults.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on the evidence for lipid management in patients with CKD, the Kidney Disease: Improving Global Outcomes (KDIGO) organization developed an updated clinical practice guideline for lipid management in CKD. 399”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [399]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Stevens, P. E., Levin, A., & for the Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00007 · Cited by 3,607
Self-citationAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Self-citationADOLESCENTS, E. P. O. I. G. F. C. H. A. R. R. I. C. A. (2011) · Pediatrics · doi:10.1542/peds.2009-2107c · Cited by 2,585
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Self-citationRosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Research works printed but not linked: 1
- Coresh J, 1998, J Am Soc Nephrol, 9, S24
Cited by
Items 101–200 of 230
Ruiz‐García, A., Arranz-Martínez, E., Merchante, I. M., Fuster, V. P., Tamarit, J. J., Trias, F., Pintó, X., & Ascaso, J. F. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.06.006 · Cited by 14
Lipoprotein modulation of proteinuric renal injury
Tsuchida, Y., Zhong, J., Otsuka, T., Dikalova, A., Pastan, I. H., Anantharamaiah, G. M., Linton, M. F., Yancey, P. G., Ikizler, T. A., Fogo, A. B., et al. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0253-6 · Cited by 11
Mathew, R. O., Maron, D. J., Anthopolos, R., Fleg, J. L., O’Brien, S. M., Rockhold, F. W., Briguori, C., Roik, M. F., Mazurek, T., Demkow, M., et al. (2022) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.122.008995 · Cited by 11
Toplak, H., Ludvik, B. H., Lechleitner, M., Dieplinger, H., Föger, B., Paulweber, B., Weber, T., Watschinger, B., Horn, S., Wascher, T. C., et al. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-0993-x · Cited by 15
Schuchardt, M., Tölle, M., & van der Giet, M. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_13 · Cited by 13
“Recent guidelines for the management of lipid disorders in patients with chronic renal failure recommend lipid-lowering therapy only in patients with CKD who are not undergoing renal replacement therapy (National Kidney Foundation 2003; Tonelli and Wanner 2013).”
BackgroundDyslipidemia in Chronic Kidney Disease
Streja, E., & Streja, D. A. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch34 · Cited by 12
Владиславович, Е. М., Kukharchuk, V. V., Балахонова, Т. В., Gurevich, V. S., Сергиенко, И. В., Sokolov, A. A., Анатольевич, С. А., Иосифович, Ш. И., Ахмеджанов, Н. М., Барбараш, О. Л., et al. (2025) · Eurasian heart journal · doi:10.38109/2225-1685-2025-2-6-34 · Cited by 11
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Hegbrant, J., & Strippoli, G. F. (2015) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.20151336t2 · Cited by 10
Cashmore, B. A., Tunnicliffe, D. J., Palmer, S. C., Blythen, L., Boag, J., Kostner, K., Krishnasamy, R., Lambert, K., Miller, A., Mullan, J., et al. (2024) · Nephrology · doi:10.1111/nep.14295 · Cited by 10
“…equation O n l y d a t a f r o m o n e s t ud y . g S y s t e m a t i c r e v i e w [ 1 ] w i t h i n c l ud e d s t ud i e s : [ 51 ] , [ 16 ] , [ 26 ] , [ 9 ] , [ 36 ] , [ 57 ] , [ 55 ] , [ 50 ] , [ 10 ] , [ 38 ] , [ 49 ] , [ 35 ] , [ 30 ] , [ 6 ] B a s e l i n e / c o m p a r a t o r P r i m a…”
Outcomes in Patients with Chronic Kidney Disease After Liver Resection for Hepatocellular Carcinoma
Yoshikawa, T., Nomi, T., Hokuto, D., Kamitani, N., Matsuo, Y., & Sho, M. (2020) · World Journal of Surgery · doi:10.1007/s00268-020-05829-z · Cited by 10
Nash, D. M., Ivers, N. M., Young, J., Jaakkimainen, R. L., Garg, A. X., & Tu, K. (2017) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358117699833 · Cited by 10
Conte, C., Maggiore, U., Cappelli, G., Ietto, G., Lai, Q., Salis, P., Marchetti, P., Piemonti, L., Secchi, A., Capocasale, E., et al. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.05.004 · Cited by 10
“indicated by the KDIGO Clinical Practice Guideline for Lipid Management in CKD [109].”
MethodResultInfluentialZijlstra, L. E., Trompet, S., Mooijaart, S. P., van Buren, M., & Jukema, J. W. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.11.010 · Cited by 10
Choi, Y., Jacobs, D. R., Kramer, H., Shroff, G. R., Chang, A. R., & Duprez, D. A. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.12.001 · Cited by 9
Jiang, Z., Wu, Z., Liu, R., Du, Q., Fu, X., Li, M., Kuang, Y., Lin, S., Wu, J., Xie, W., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1102810 · Cited by 9
Cuevas, A. M., Arteaga, A., & Rigotti, A. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0400-x · Cited by 9
Dyslipidemia in chronic kidney disease
Kowalski, A., Krikorian, A., & Lerma, E. V. (2015) · Disease-a-Month · doi:10.1016/j.disamonth.2015.07.004 · Cited by 14
Gierach, M., Gierach, J., & Junik, R. (2015) · Endokrynologia Polska · doi:10.5603/ep.a2016.0020 · Cited by 9
Kim, J. Y., Steingroever, J., Lee, K. H., Oh, J. S., Choi, M., Lee, J. M., Larkins, N., Schaefer, F. S., Hong, S. H., Jeong, G. H., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020394 · Cited by 10
Sriwijitkamol, A., & Sangsawang, T. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s92461 · Cited by 9
Lin, Y.-C., Lai, T.-S., Chen, Y.-T., Chou, Y.-H., Chen, Y.-M., Hung, K.-Y., & Tu, Y.-K. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2024.09.037 · Cited by 10
Effect of statins on survival in patients undergoing dialysis access for end-stage renal disease
Rango, P. D., Parente, B., Farchioni, L., Cieri, E., Fiorucci, B., Pelliccia, S., Manzone, A., Simonte, G., & Lenti, M. (2016) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2017.03.001 · Cited by 8
Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now
Waters, D. D. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.07.477 · Cited by 9
Lipids, inflammation, and chronic kidney disease: a SHARP perspective
Waters, D. D., & Vogt, L. (2018) · Kidney International · doi:10.1016/j.kint.2017.11.031 · Cited by 8
Intensity-Dependent Benefit of Statins in Survival Among Prospective Kidney Transplant Patients
Co, M. L., Agdamag, A. C., Co, M. Z., Hertl, M., & Mohamedali, B. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.09.037 · Cited by 8
Funamizu, T., Iwata, H., Chikata, Y., Doi, S., Endo, H., Wada, H., Naito, R., Ogita, M., Kato, Y., Okai, I., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020390 · Cited by 8
“Accordingly, despite no recommendation concerning the initiation of statins, guidelines paradoxically encourage the continuation of statins in patients who were already receiving them before the introduction of dialysis [12,16,17,25].”
BackgroundKampmann, J. D., Nybo, M., Brandt, F., Støvring, H., Damkier, P., Henriksen, D. P., & Lund, L. C. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13768 · Cited by 8
Palmer, S. C., Craig, J. C., Jones, A., Higgins, G. Y., Willis, N. S., & Strippoli, G. F. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu232 · Cited by 7
Brar, A., Santana, J. M., Salifu, M. O., & Brown, C. D. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82831 · Cited by 7
“Kidney Disease Improving Global Outcomes (KDIGO) suggest treatment with statins in adult kidney transplant recipients [77].”
BackgroundSong, J. H., Park, E. H., Bae, J., Kwon, S. H., Cho, J., Yu, B. C., Han, M., Song, S. H., Ko, G.-J., Yang, J. W., et al. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03337-5 · Cited by 8
Lipid clinical trials with special reference to Indian population
Aseem Basha, M., & Ramakrishnan, S. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.02.003 · Cited by 7
Klose, G., Beil, F. U., Dieplinger, H., von Eckardstein, A., Föger, B., Gouni‐Berthold, I., Köenig, W., Kostner, G. M., Landmesser, U., Laufs, U., et al. (2014) · Der Internist · doi:10.1007/s00108-014-3492-z · Cited by 7
Self-citationStatins: Practical Considerations – A Review
Abdullah, K., & Rohatgi, A. K. (2014) · European Cardiology Review · doi:10.15420/ecr.2014.9.2.71 · Cited by 9
Kim, K. W., Koh, H. B., Kim, H. W., Park, J. T., Yoo, T., Kang, S., Oh, K., Hyun, Y. Y., Jung, J. Y., Sung, S. A., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01230-0 · Cited by 8
Management of Chronic Heart Failure in Dialysis Patients: A Challenging but Rewarding Path
Guo, L., Ji, Y., Sun, T., Liu, Y., Jiang, C., Wang, G., Xing, H., Yang, B., Ao, X., Xian, X., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2506232 · Cited by 7
“Recent guidelines [ 117–120] do not recommend the use of lipid-lowering agents in dialysis patients but recommend patients who receive statin therapy at the beginning of dialysis continue to use statin therapy [ 121].”
BackgroundCurrent Controversies With Recent Cholesterol Treatment Guidelines
Phillips, E., & Saseen, J. J. (2015) · Journal of Pharmacy Practice · doi:10.1177/0897190015615880 · Cited by 6
Yang, W., Zhu, X., Zhu, N., Su, C., Han, Q., Wang, T., & Zhang, A. H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167258 · Cited by 6
Ye, H., Wu, H., Peng, Y., Zhou, Q., Cao, P., Guo, Q., Mao, H., Yu, X.-Q., & Yang, X. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.08.028 · Cited by 6
Progressionshemmung bei chronischen Nierenerkrankungen
Saritas, T., & Floege, J. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01482-5 · Cited by 6
Opinions of nephrologists on the efficacy and tolerance of statins in hemodialysis patients
Budzisz, E., & Nowicki, M. P. (2016) · Renal Failure · doi:10.1080/0886022x.2016.1260032 · Cited by 6
Galán, I., Verdalles, Ú., de Vinuesa, M. G., Quiroga, B., Goicoechea, M., Pérez, A., Verde, E., & Luño, J. (2018) · Nefrología · doi:10.1016/j.nefro.2017.10.003 · Cited by 5
Locatelli, F., & Vecchio, L. D. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1029456 · Cited by 5
Айтбаев, К. А., Murkamilov, I. T., & Fomin, V. V. (2019) · Kardiologiia · doi:10.18087/cardio.2019.2.10231 · Cited by 7
Medical Management of the Kidney Transplant Recipient
Pedraza, F., & Roth, D. (2014) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2014.08.009 · Cited by 6
Streja, E., Streja, D. A., Soohoo, M., Kleine, C., Hsiung, J., Park, C., & Moradi, H. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.05.007 · Cited by 5
The Association of Niacin Use with Kidney Outcomes and Mortality
Takahashi, R., Bui, T.-A., Elali, I., Tran, D., Sumida, K., Thomas, F., Dukkipati, R. B., Shah, A. P., Rhee, C. M., Kovesdy, C. P., et al. (2025) · American Journal of Nephrology · doi:10.1159/000543098 · Cited by 4
Khrulev, A. Е., Шиянова, Н. А., Grigorieva, V. N., Н., В. Г., Kоzulina, L. S., & Egorskaya, A. T. (2022) · Russian neurological Journal · doi:10.30629/2658-7947-2022-27-2-43-52 · Cited by 5
Special considerations for the treatment of chronic kidney disease in the elderly
Corsonello, A., Fusco, S., Bustacchini, S., Chiatti, C., Moresi, R., Bonfigli, A. R., Stefano, G. D., & Lattanzio, F. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1155448 · Cited by 7
Milinković, N., Sarić, M., Jovičić, S. Ž., Mirković, D., Ležaić, V., & Ignjatović, S. (2019) · Journal of Medical Biochemistry · doi:10.2478/jomb-2019-0032 · Cited by 5
Clearance of cardiovascular medications during hemodialysis
Tieu, A., Leither, M. D., Urquhart, B. L., & Weir, M. A. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000216 · Cited by 4
Cardiovascular Disease Prevention in CKD
Hallan, S. I. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.06.005 · Cited by 4
“Overall, the study by Tonelli et al3 is solid and gives an important contribution to cardiovascular prevention in CKD.”
BackgroundInfluentialWe Don’t Prescribe Statins to Lower Cholesterol: We Prescribe Statins to Reduce Vascular Risk
Tonelli, M. A. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014090952 · Cited by 4
Self-citationApplication of the new cholesterol guidelines.
Navar‐Boggan, A. M., Sniderman, A. D., & Pencina, M. J. (2014) · PubMed · doi:10.1056/nejmc1405680 · Cited by 3
Lipoprotein(a) and kidney diseases
Pyatchenkov, M. O., Rumyantsev, A. S., Владимирович, З. М., Sherbakov, E. V., & Belskykh, A. N. (2021) · Nephrology (Saint-Petersburg) · doi:10.36485/1561-6274-2021-25-1-31-46 · Cited by 3
Prediction model for radial-cephalic arteriovenous fistula failure to mature
Zeng, W., Zhang, B., Wang, X., Wang, R., Niu, Y., Yue, X., Liang, X., & Wang, P. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2559124 · Cited by 3
Assanto, E., Brigato, C., Gammaitoni, G., Pellicano, C., Rosato, E., Iannazzo, F., Muscaritoli, M., Cianci, R., & Gigante, A. (2025) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-025-00771-4 · Cited by 3
Ballegaard, E. L. F., Carlson, N., Jørgensen, M. B., Sørensen, I. M. H., Trankjær, H., Almarsdóttir, A. B., Bro, S., Feldt‐Rasmussen, B., Kamper, A., & for The Copenhagen CKD Cohort Study Group (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae158 · Cited by 3
“Lipid-lowering treatment is suggested or recommended in specific CKD subgroups irrespective of plasma lipid levels [9 ].”
BackgroundMethodInfluentialFeldman, H. A., Zuber, K., & Davis, J. S. (2017) · Physician Assistant Clinics · doi:10.1016/j.cpha.2017.06.004 · Cited by 5
Li, W., Bai, W., Miao, C., Chen, S., Zhang, X., Fan, Y., Li, X., Wu, S., Liu, X., & Jiang, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.943718 · Cited by 3
Little, D. J., Yuan, C. M., Thurlow, J. S., Gounden, V., Doi, S. Q., Pruziner, A. L., Abbott, K. C., Theeler, B. J., & Olson, S. W. (2015) · American Journal of Nephrology · doi:10.1159/000443775 · Cited by 3
NEW POSSIBILITIES OF HYPOLIPIDEMIC THERAPY
Benimetskaya, K., Atyukov, P. A., Astrakov, S. V., & Ragino, Y. I. (2017) · Siberian medical review · doi:10.20333/2500136-2017-4-65-81 · Cited by 5
Mannheimer, E. E., Jørgensen, M. B., Hommel, K., Kamper, A., Jepsen, R., Feldt‐Rasmussen, B., & Hornum, M. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf242 · Cited by 2
“Statins were indicated for individuals aged 50 and older or for younger individuals with CVD risk factors such as diabetes, prior ischemic stroke, coronary artery disease, or an estimated 10-year risk of coronary death or non-fatal myocardial infarction greater than 10% [20 ].”
Kumada, Y., Kawai, N., Ishida, N., Mori, A., Ishii, H., Ohshima, S., Ito, R., Umemoto, N., Takahashi, H., & Murohara, T. (2022) · Angiology · doi:10.1177/00033197211070882 · Cited by 2
“Based on these findings, the Kidney Disease: Improving Global Outcomes guidelines do not recommend statins therapy for chronic hemodialysis patients.(23) There are several limitations in this study.”
BackgroundJairoun, A. A., Ping, C. C., Ibrahim, B., Jawamis, D. F. A., Jaberi, A. K. A., Dawoud, T. H., Mohammed, K. J., El‐Dahiyat, F., & Shahwan, M. J. (2024) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2024.2414293 · Cited by 2
Dahl, J. N., Nissen, L., Nielsen, M. B., Rasmussen, L. D., Søby, J. H., Birn, H., Bøttcher, M., & Winther, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf218 · Cited by 2
STATINS IN CHRONIC KIDNEY DISEASE. IS THERE A DRUG OF CHOICE?
Drapkina, O. M., & Корнеева, О. Н. (2015) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2015-6-78-82 · Cited by 2
Chen, S.-P., Li, C., Chang, C.-M., Li, Y.-L., & Pai, H. (2018) · Clinical Nursing Research · doi:10.1177/1054773818773385 · Cited by 2
“…in one of five stages, from G1 to G5, as follows: G1: ≥90 (normal or high), G2: 60 to 90 (mildly decreased), G3a: 45 to 59 (mildly to moderately decreased), G3b: 30 to 44 (moderately to severely decreased), G4: 15 to 29 (severely decreased), and G5: <15 (kidney failure; Tonelli & Wanner, 2014).”
Treatment Goals in Diabetic Nephropathy
Vervoort, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-93521-8_25 · Cited by 2
Fallahzadeh, M. K., Ku, E., Chu, C. D., McCulloch, C. E., & Tuot, D. S. (2022) · Kidney Medicine · doi:10.1016/j.xkme.2022.100438 · Cited by 2
“Management in Chronic Kidney Disease published in 2013 was the first guideline that suggested treating all adult kidney transplant recipients with a statin.(11) There con-”
BackgroundTopical issues concerning modern lipid-lowering therapy
Susekov, A. V. (2022) · Consilium Medicum · doi:10.26442/20751753.2022.1.201484 · Cited by 2
Lee, D., Huang, C., Yeh, W., Sung, S., Chen, C., & Cheng, H. (2022) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000840 · Cited by 2
Khedri, M., Szummer, K. E., Lundman, P., Jernberg, T., Desta, L., Lindahl, B., Erlinge, D., Jacobson, S. H., & Spaak, J. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001402 · Cited by 2
Lin, Y., Tsao, H., Lai, T., Chen, Y., Chou, Y., Lin, S., Chen, Y., Hung, K., & Tu, Y. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3060 · Cited by 2
“13,14 20 Despite these positive results, whether the reduction in the risk of MACEs is due to the blood lipid–lowering effect of LLDs or a direct effect of LLDs, independent of changes in blood lipid levels, is unclear.”
BackgroundLipid-Lowering Guidelines and Statin Use in CKD: A Time for Change
Baber, U., & Muntner, P. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.02.001 · Cited by 2
“Although the ATP III guideline was the cholesterol guideline in place at the time the study by Foster et al(8) was conducted, future studies should examine the findings of Foster et al(8) within the context of the 2013 ACC/AHA and the KDIGO (Kidney Disease: Improving Global Outcomes) lipid-lowering guidelines.(5,18) R…”
MethodResultROSUVASTATIN - THE MOST POTENT STATIN IN CARDIOVASCULAR DISEASE PREVENTION
Семенова, А. Е., & Сергиенко, И. В. (2018) · Eurasian heart journal · doi:10.38109/2225-1685-2018-2-28-41 · Cited by 2
Rivera, M., Tamariz, L. J., Suarez, M., & Contreras, G. N. (2019) · American Journal of Nephrology · doi:10.1159/000499188 · Cited by 2
Ахмеджанов, Н. М., Vezikova, N. N., Voevoda, M. I., Galyavich, A. S., Gurevich, V. S., Duplyakov, D. V., Владиславович, Е. М., IuA, K., Кашталап, В. В., Konovalov, G. A., et al. (2019) · Kardiologiia · doi:10.18087/cardio.n308 · Cited by 1
Böbrek Hastalıkları ve Lipit Metabolizması
Saka, M. (2019) · Journal of Nutrition and Dietetics · doi:10.33076/2018.bdd.1166 · Cited by 1
Eliminating Missed Opportunities for CKD Care
Kramer, H., & Markossian, T. W. (2019) · Kidney Medicine · doi:10.1016/j.xkme.2019.07.008 · Cited by 1
Heart and kidney disease: a cardiovascular high-risk constellation
Schunk, S. J., Speer, T., & Fliser, D. (2020) · Herz · doi:10.1007/s00059-020-05012-z · Cited by 1
Kardiovaskuläre Therapie bei chronischer Nierenerkrankung
Brandenburg, V. M., Saritas, T., Schirmer, S. H., Rogacev, K. S., & Heine, G. H. (2023) · Herz · doi:10.1007/s00059-023-05205-2 · Cited by 1
Sowa, P. M., Mallett, A. J., & Connelly, L. B. (2024) · Genetics in Medicine Open · doi:10.1016/j.gimo.2024.101876 · Cited by 1
PCSK9 inhibitors for LDL lowering
Walsh, J. P. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.02.001 · Cited by 1
“A trial of PCSK9 inhibitors in patients with advanced renal disease, a population in which the benefits of statins are unclear, would also be worthwhile (22).”
BackgroundConte, C., Maggiore, U., Cappelli, G., Ietto, G., Lai, Q., Salis, P., Marchetti, P., Piemonti, L., Secchi, A., Capocasale, E., et al. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00839-5 · Cited by 1
Aliakbari, F., Moosazadeh, M., Alatab, S., Poustchi, H., Masoudi, S., Mohammadi, Z., Kebar, S. M., Naghashi, S., Eftekhar, E., Moradpour, A., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5304493/v1 · Cited by 1
Merino, J. L., Lozano, E., Domínguez, P., Amezquita, Y. M., Bueno, B., Espejo, B., & Paraíso, V. (2015) · Diálisis y Trasplante · doi:10.1016/j.dialis.2015.02.003
The role of the food lipid component in the progression of chronic renal failure
Bruzzese, A., Montuori, F., Barillari, M., Buemi, M., & Santoro, D. (2015) · Giornale di Techniche Nefrologiche e Dialitiche · doi:10.5301/gtnd.2015.13066
Cholesterol: "targeting" the enemy.
Kallikazaros, I. E. (2014) · PubMed
Pharmacological treatments and monitoring strategies to improve outcome in solid organ transplants
Robertsen, I. (2014) · NORA - Norwegian Open Research Archives
Lepeytre, F., Cardinal, H., Fradette, L., Verhave, J. C., Dorais, M., LeLorier, J., Pichette, V., & Madore, F. (2016) · Clinical Kidney Journal · doi:10.1093/ckj/sfw144
“Actual guidelines on management of CKD emphasize the importance of recognizing and addressing cardiovascular risk factors using appropriate cardioprotective drug therapy, with consideration for aggressive blood pressure and lipid management [6, 7].”
BackgroundJung, C. H. (2017) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2017.6.1.8
Ortíz, A. (2018) · Wiley eBooks · doi:10.1002/9781119183952.ch19
Summary of the 2018 ISN Frontiers Meeting: Kidney Disease and Cardiovascular Disease
Kume, S., Nagasu, H., Nangaku, M., Nishiyama, A., Nakamoto, H., & Kashihara, N. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.04.002
DIABETES MELLITUS, DIABETIC NEPHROPATHY, CHILDREN: CERTAINISSUES
Fomina, A. (2017) · Ukrainian Journal of Nephrology and Dialysis · doi:10.31450/ukrjnd.1(53).2017.09
Drugs for Treatment of Dyslipidemia Available in the USA
Streja, E., & Streja, D. A. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_13
Lipid-lowering therapy in selected specific groups of patients
Kraml, P. J. (2020) · Medicína pro praxi · doi:10.36290/med.2020.029
Улога на метаболичниот синдром во развој и прогресија на хроничната бубрежна слабост
Prosheva, T. B., & Тозија, Л. (2015) · Macedonian Medical Electronic Journal · doi:10.3889/mmej.2015.50005
Diabetic Kidney Disease and Cardiovascular Disease
Muta, K., Obata, Y., & Nishino, T. (2020) · Springer eBooks · doi:10.1007/978-981-15-9301-7_3 · Cited by 1
Il ruolo della componente lipidica alimentare nella progressione dell'insufficienza renale cronica
Bruzzese, A., Montuori, F., Barillari, M., Buemi, M., & Santoro, D. (2015) · Giornale di Clinica Nefrologica e Dialisi · doi:10.33393/gcnd.2015.777
Use of statins in the treatment of chronic kidney disease
Amir, M. (2021)
Metadata
- Authors
- Tonelli, M., Wanner, C., & for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members*
- Affiliations
- University of Alberta (CA)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2014-02-04
- Volume
- 160
- Issue
- 3
- Pages
- 182-189
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2159036586
- Cited by
- 226
- References
- 41
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 18 · 2023: 11 · 2022: 15 · 2021: 8 · 2020: 17 · 2019: 19 · 2018: 21 · 2017: 12 · 2016: 16 · 2015: 35 · 2014: 24
- FWCI
- 28.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Keywords
- chronic kidney disease, lipid control, statins, ezetimibe, KDIGO guidelines, hypercholesterolemia, estimated glomerular filtration rate, dialysis, kidney transplantation, cardiovascular risk
- MeSH terms
- Adult, Algorithms, Child, Coronary Disease, Glomerular Filtration Rate, Humans, Cholesterol, LDL, Middle Aged, Risk Factors, Biomarkers, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Guideline Adherence, Dyslipidemias, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.